Research programme: JNK pathway inhibitors - Aegera Therapeutics

Drug Profile

Research programme: JNK pathway inhibitors - Aegera Therapeutics

Alternative Names: AEG 3482

Latest Information Update: 02 Jun 2011

Price : $50

At a glance

  • Originator Aegera Therapeutics
  • Class Small molecules; Sulfonamides; Sulfones; Sulfoxides; Thiadiazoles
  • Mechanism of Action JNK mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Diabetic neuropathies; Neuropathic pain; Peripheral nervous system diseases

Most Recent Events

  • 25 Mar 2008 A lead compound from this programme has entered clinical development
  • 16 Mar 2007 Aegera Therapeutics initiates an accelerated screening programme to identify replacement compound(s) for AEG 33783
  • 11 Apr 2006 Data presented at the 231st ACS National Meeting (231st-ACS-2006) have been added to the Neurological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top